Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Johnson & Johnson
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Strong business, valuation above the sector
Get notified when we ship meaningful updates. No spam, no daily noise.
2 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Mixed signals
Profitability
3/4
Debt & liquidity
1/3
Efficiency
0/2
EPS growth of 90.5% — +1,136% above the sector median of 7.3% — is the sharpest growth signal here, and Debt/EBITDA of 1.6× sits -48% below the sector median 3.1×, leaving the balance sheet in better shape than most Health Care peers. The F-Score of 4/9 tells a more mixed story: profitability holds up, but the efficiency sub-scores are weak and the current ratio of 1.03 runs -26% below the sector median 1.40. On price, the P/B of 8.0× exceeds the sector median 7.2× by +11%, and the forward PEG reads as stretched — consensus models earnings growth that the realized three-year EPS CAGR in SEC filings has historically outpaced, yet the beat rate over the last eight quarters has been weak, so the forward picture carries real uncertainty. The composite of 52/100 against the sector median reflects that tension between solid fundamentals and a valuation that already prices in continued delivery.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is strengthening; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
When JNJ reports on October 13, 2026, track revenue year over year and whether EPS growth holds near the current 7.32% pace. Also check if the current ratio, now 26% below the sector median at 1.40, shows any improvement in short-term liquidity.
On SEC EDGAR, open JNJ's most recent 10-K and focus on the Leverage and Liquidity section — the F-Score flags only 1 out of 3 signals there. Cross-reference management's commentary on debt management against the reported Debt/EBITDA of 3.06×, which sits 48% below the sector median.
Pick two or three companies from the same-sector table in section 06 and line up one metric — P/B or current ratio works well given JNJ's readings of 7.17× and 1.40 respectively. The table is alphabetical with no ranking, so the comparison is yours to draw without any implied ordering.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: -13%+6%+9%-1%
Over 4 years: 1.271.141.261.61
Over 4 years: +2%+6%+4%+6%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 7 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 6/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.